Trial Profile
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children With Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Odevixibat (Primary)
- Indications Intrahepatic cholestasis
- Focus Therapeutic Use
- Acronyms PEDFIC 2
- Sponsors Albireo AB; Albireo Pharma
- 21 Mar 2024 This trial has been completed in France, according to European Clinical Trials Database record.
- 17 Jan 2024 Planned End Date changed from 30 Mar 2024 to 31 Mar 2025.
- 17 Jan 2024 Planned primary completion date changed from 30 Mar 2024 to 31 Mar 2024.